Clinical trials: Acute Porphyria
Anti-Psychotic, Management of Manifestations of Psychotic Disorders
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
Cycle Pharmaceuticals Ltd. (Cycle) is developing an oral tablet formulation of Chlorpromazine Hydrochloride and intends to conduct bioequivalence trials to demonstrate its similarity to the RLD.
- Conditions
- Anti-Psychotic, Management of Manifestations of Psychotic Disorders, Treatment of Schizophrenia, Control Nausea and Vomiting
- Trial name
- NCT02943213
- Testing
- Chlorpromazine Hydrochloride
- Where
- South Africa
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cycle Pharmaceuticals Ltd.
Porphyrias, Hepatic
Acute Intermittent Porphyria Related Abnormalities in Cardiovascular System
This study aims to assess the changes in the cardiovascular system in patients with acute intermittent porphyria (AIP).
- Trial name
- AIPRACUS (NCT05882136)
- Where
- 2 sites in Poland
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Acute Intermittent Porphyria
Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)
Acute intermittent porphyria (AIP) is an autosomal dominant inherited disease, which is relatively prevalent in northern Norway with a total of around 90 patients. This provides us with a special opportunity to study AIP.
- Trial name
- NCT01617642
- Where
- Norway
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Nordlandssykehuset HF